Current status of PET-imaging probes of β-amyloid plaques

Archives of Pharmacal Research

Volumn 36, Issue 10, 2013, Pages 1178-1184

  Koo, Jaehyung ^a   Byun, Youngjoo ^b  

^a Daegu Gyeongbuk Institute of Science and Technology   (South Korea)

^b Korea University   (South Korea)

Author keywords

Alzheimer's disease; Amyloid plaques; PET imaging

Indexed keywords

AZD 4694; BAY 1008472; BENZENE; CARBON 11; FLORBETAPIR F 18; FLUORINE 18; FLUTEMETAMOL F 18; HYDROXYL GROUP; MACROGOL; PIPERAZINE DERIVATIVE; PYRIDINE; PYRIDINYLBENZOXAZOLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; STILBENE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; BINDING AFFINITY; DEMENTIA; EARLY DIAGNOSIS; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; METABOLIC RATE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; ANILINE COMPOUNDS; ETHYLENE GLYCOLS; HUMANS; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY;

EID: 84885954117     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0193-4     Document Type: Review

References (37)

1. Akiyama, H., S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, N.R. Cooper, P. Eikelenboom, M. Emmerling, B.L. Fiebich, C.E. Finch, S. Frautschy, W.S.T. Griffin, H. Hampel, M. Hull, G. Landreth, L.F. Lue, R. Mrak, I.R. Mackenzie, P.L. Mcgeer, M.K. O'banion, J. Pachter, G. Pasinetti, C. Plata-Salaman, J. Rogers, R. Rydel, Y. Shen, W. Streit, R. Strohmeyer, I. Tooyoma, F.L. Van Muiswinkel, R. Veerhuis, D. Walker, S. Webster, B. Wegrzyniak, G. Wenk, T. Wyss-Coray, and N.W. Grp. 2000. Inflammation and Alzheimer's disease. Neurobiology of Aging 21: 383-421.
2. Alzheimer, A. 1907. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin 64: 146-148.
3. Brockschnieder, D., H. Schmitt-Willich, T. Heinrich, A. Varrone, B. Gulyas, M. Toth, J. Andersson, U. Boemer, S. Krause, M. Friebe, L. Dinkelborg, C. Halldin, and T. Dyrks. 2012. Preclinical characterization of a novel class of F-18-labeled PET tracers for amyloid-beta. Journal of Nuclear Medicine 53: 1794-1801.
4. Broersen, K., F. Rousseau, and J. Schymkowitz. 2010. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Alzheimers Research and Therapy 2: 12.
5. Camus, V., P. Payoux, L. Barre, B. Desgranges, T. Voisin, C. Tauber, R. La Joie, M. Tafani, C. Hommet, G. Chetelat, K. Mondon, V. De La Sayette, J.P. Cottier, E. Beaufils, M.J. Ribeiro, V. Gissot, E. Vierron, J. Vercouillie, B. Vellas, F. Eustache, and D. Guilloteau. 2012. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. European Journal of Nuclear Medicine and Molecular Imaging 39: 621-631.
6. Citron, M., T.S. Diehl, G. Gordon, A.L. Biere, P. Seubert, and D.J. Selkoe. 1996. Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proceedings of the National Academy of Sciences USA 93: 13170-13175.
7. Cui, M.C., M. Ono, H. Kimura, M. Ueda, Y. Nakamoto, K. Togashi, Y. Okamoto, M. Ihara, R. Takahashi, B.L. Liu, and H. Saji. 2012a. Novel F-18-labeled benzoxazole derivatives as potential positron emission tomography probes for imaging of cerebral beta-amyloid plaques in Alzheimer's disease. Journal of Medicinal Chemistry 55: 9136-9145.
8. Cui, M.C., X.D. Wang, P.R. Yu, J.M. Zhang, Z.J. Li, X.J. Zhang, Y.P. Yang, M. Ono, H.M. Jia, H. Saji, and B.L. Liu. 2012b. Synthesis and evaluation of novel F-18 labeled 2-pyridinylbenzoxazole and 2-pyridinylbenzothiazole derivatives as ligands for positron emission tomography (pet) imaging of beta-amyloid plaques. Journal of Medicinal Chemistry 55: 9283-9296.
9. Doi, Y., T. Mizuno, Y. Maki, S. Jin, H. Mizoguchi, M. Ikeyama, M. Doi, M. Michikawa, H. Takeuchi, and A. Suzumura. 2009. Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid beta neurotoxicity in in vitro and in vivo models of Alzheimer's disease. American Journal of Pathology 175: 2121-2132.
10. Galimberti, D., and E. Scarpini. 2011. Inflammation and oxidative damage in Alzheimer's disease: friend or foe? Frontiers in Bioscience (Scholar Edition) 3: 252-266.
11. Gomez-Isla, T., R. Hollister, H. West, S. Mui, J.H. Growdon, R.C. Petersen, J.E. Parisi, and B.T. Hyman. 1997. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Annals of Neurology 41: 17-24.
12. Gomez-Isla, T., J.L. Price, D.W. Mckeel, J.C. Morris, J.H. Growdon, and B.T. Hyman. 1996. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. Journal of Neuroscience 16: 4491-4500.
13. Hauser, S.L., S.A. Josephson, and S.C. Johnston. 2012. Florbetapir: knowing one's future. Annals of Neurology 71: A6.
14. Herholz, K. 2012. Imaging cerebral amyloid plaques: clinical perspective. Lancet Neurology 11: 652-653.
15. Herholz, K., and K. Ebmeier. 2011. Clinical amyloid imaging in Alzheimer's disease. Lancet Neurology 10: 667-670.
16. Hsiao, I.T., C.C. Huang, C.J. Hsieh, S.P. Wey, M.P. Kung, T.C. Yen, and K.J. Lin. 2013. Perfusion-like template and standardized normalization-based brain image analysis using (18)F-florbetapir (AV-45/Amyvid) PET. European Journal of Nuclear Medicine and Molecular Imaging 40: 908-920.
17. Jureus, A., B.M. Swahn, J. Sandell, F. Jeppsson, A.E. Johnson, P. Johnstrom, J.A.M. Neelissen, D. Sunnemark, L. Farde, and S.P.S. Svensson. 2010. Characterization of AZD4694, a novel fluorinated A beta plaque neuroimaging PET radioligand. Journal of Neurochemistry 114: 784-794.
18. Kingwell, K. 2012. Alzheimer disease: Florbetapir-a useful tool to image amyloid load and predict cognitive decline in Alzheimer disease. Nature Review Neurology 8: 471.
19. Koole, M., D.M. Lewis, C. Buckley, N. Nelissen, M. Vandenbulcke, D.J. Brooks, R. Vandenberghe, and K. Van Laere. 2009. Whole-body biodistribution and radiation dosimetry of F-18-GE067: A radioligand for in vivo brain amyloid imaging. Journal of Nuclear Medicine 50: 818-822.
20. La Joie, R., A. Perrotin, L. Barre, C. Hommet, F. Mezenge, M. Ibazizene, V. Camus, A. Abbas, B. Landeau, D. Guilloteau, V. De La Sayette, F. Eustache, B. Desgranges, and G. Chetelat. 2012. Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia. Journal of Neuroscience 32: 16265-16273.
21. Landau, S.M., M.A. Mintun, A.D. Joshi, R.A. Koeppe, R.C. Petersen, P.S. Aisen, M.W. Weiner, and W.J. Jagust. 2012. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annals of Neurology 72: 578-586.
22. Lee, I., Y.S. Choe, J.Y. Choi, K.H. Lee, and B.T. Kim. 2012. Synthesis and evaluation of F-18-labeled styryltriazole and resveratrol derivatives for beta-amyloid plaque imaging. Journal of Medicinal Chemistry 55: 883-892.
23. Liu, Y., L. Zhu, K. Plossl, S.R. Choi, H. Qiao, X. Sun, S. Li, Z. Zha, and H.F. Kung. 2010. Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer's disease. Nuclear Medicine and Biology 37: 917-925.
24. Matsumura, K., M. Ono, H. Kimura, M. Ueda, Y. Nakamoto, K. Togashi, Y. Okamoto, M. Ihara, R. Takahashi, and H. Saji. 2012. F-18-labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains. ACS Medicinal Chemistry Letters 3: 58-62.
25. McLean, D., M.J. Cooke, R. Albay 3rd, C. Glabe, and M.S. Shoichet. 2013. Positron emission tomography imaging of fibrillar parenchymal and vascular amyloid-beta in TgCRND8 mice. ACS Chemical Neuroscience 4: 613-623.
26. Newberg, A.B., S.E. Arnold, N. Wintering, B.W. Rovner, and A. Alavi. 2012. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. Journal of Nuclear Medicine 53: 902-907.
27. Ramanan, V.K., S.L. Risacher, K. Nho, S. Kim, S. Swaminathan, L. Shen, T.M. Foroud, H. Hakonarson, M.J. Huentelman, P.S. Aisen, R.C. Petersen, R.C. Green, C.R. Jack, R.A. Koeppe, W.J. Jagust, M.W. Weiner, and A.J. Saykin. 2013. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Molecular Psychiatry. doi: 10.1038/mp.2013.19.
28. SantaCruz, K., J. Lewis, T. Spires, J. Paulson, L. Kotilinek, M. Ingelsson, A. Guimaraes, M. Deture, M. Ramsden, E. Mcgowan, C. Forster, M. Yue, J. Orne, C. Janus, A. Mariash, M. Kuskowski, B. Hyman, M. Hutton, and K.H. Ashe. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309: 476-481.
29. Thompson, C.A. 2012. Radioactive agent approved as part of Alzheimer disease workup. American Journal of Health System Pharmacy 69: 818.
30. Tuppo, E.E., and H.R. Arias. 2005. The role of inflammation in Alzheimer's disease. International Journal of Biochemistry and Cell Biology 37: 289-305.
31. Vandenberghe, R., K. Van Laere, A. Ivanoiu, E. Salmon, C. Bastin, E. Triau, S. Hasselbalch, I. Law, A. Andersen, A. Korner, L. Minthon, G. Garraux, N. Nelissen, G. Bormans, C. Buckley, R. Owenius, L. Thurfjell, G. Farrar, and D.J. Brooks. 2010. F-18-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment a phase 2 trial. Annals of Neurology 68: 319-329.
32. Wolk, D.A., Z. Zhang, S. Boudhar, C.M. Clark, M.J. Pontecorvo, and S.E. Arnold. 2012. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. Journal of Neurology, Neurosurgery and Psychiatry 83: 923-926.
33. Wong, C.W., V. Quaranta, and G.G. Glenner. 1985. Neuritic plaques and cerebrovascular amyloid in Alzheimer-disease are antigenically related. Proceedings of the National Academy of Sciences USA 82: 8729-8732.
34. Wong, D.F., P.B. Rosenberg, Y. Zhou, A. Kumar, V. Raymont, H.T. Ravert, R.F. Dannals, A. Nandi, J.R. Brasic, W.G. Ye, J. Hilton, C. Lyketsos, H.F. Kung, A.D. Joshi, D.M. Skovronsky, and M.J. Pontecorvo. 2010. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand F-18-AV-45 (flobetapir F 18). Journal of Nuclear Medicine 51: 913-920.
35. Yin, W., X. Zhou, J.P. Qiao, and L. Zhu. 2012. Study the pharmacokinetics of AV-45 in rat plasma and metabolism in liver microsomes by ultra-performance liquid chromatography with mass spectrometry. Biomedical Chromatography 26: 666-671.
36. Zhang, W., M.P. Kung, S. Oya, C. Hou, and H.F. Kung. 2007. F-18-labeled styrylpyridines as PET agents for amyloid plaque imaging. Nuclear Medicine and Biology 34: 89-97.
37. Zhang, W., S. Oya, M.P. Kung, C. Hou, D.L. Maier, and H.F. Kung. 2005. F-18 polyethyleneglycol stilbenes as PET imaging agents targeting A beta aggregates in the brain. Nuclear Medicine and Biology 32: 799-809.